RAPP Rapport Therapeutics Inc.

Price (delayed)

$37.595

Market cap

$1.8B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.59

Enterprise value

$1.73B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 32

We are a clinical-stage biopharmaceutical company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (“CNS”) disorders. Neuronal receptors are complex assemblies ...

Highlights
Rapport Therapeutics's EPS has increased by 14% YoY and by 9% from the previous quarter
Rapport Therapeutics's equity has soared by 65% YoY but it has decreased by 2.7% from the previous quarter
Rapport Therapeutics's debt has increased by 38% YoY but it has decreased by 6% from the previous quarter

Key stats

What are the main financial stats of RAPP

RAPP stock price

How has the Rapport Therapeutics stock price performed over time
Intraday
1.61%
1 week
-4.8%
1 month
5.81%
1 year
187.86%
YTD
23.91%
QTD
20.15%

Financial performance

How have Rapport Therapeutics's revenue and profit performed over time
Revenue
$20M
Gross profit
$20M
Operating income
-$122.21M
Net income
-$107.28M
Gross margin
100%
Net margin
-536.4%
The net income has contracted by 35% YoY but it has grown by 3.8% from the previous quarter
Rapport Therapeutics's operating income has decreased by 31% YoY but it has increased by 2.3% QoQ

Price vs fundamentals

How does RAPP's price correlate with its fundamentals

Growth

What is Rapport Therapeutics's growth rate over time

Valuation

What is Rapport Therapeutics stock price valuation
P/E
N/A
P/B
3.81
P/S
88.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
86.53
Rapport Therapeutics's EPS has increased by 14% YoY and by 9% from the previous quarter
Rapport Therapeutics's equity has soared by 65% YoY but it has decreased by 2.7% from the previous quarter
RAPP's P/B is 50% higher than its last 4 quarters average of 2.5

Efficiency

How efficient is Rapport Therapeutics business performance
The company's return on invested capital rose by 16% QoQ
The ROA has increased by 14% QoQ and by 4.9% YoY
Rapport Therapeutics's ROE has increased by 14% from the previous quarter and by 2.7% YoY

Dividends

What is RAPP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RAPP.

Financial health

How did Rapport Therapeutics financials performed over time
The total assets has surged by 65% year-on-year but it has declined by 2.9% since the previous quarter
RAPP's total liabilities has surged by 61% year-on-year but it is down by 6% since the previous quarter
Rapport Therapeutics's debt is 98% less than its equity
Rapport Therapeutics's equity has soared by 65% YoY but it has decreased by 2.7% from the previous quarter
Rapport Therapeutics's debt has increased by 38% YoY but it has decreased by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.